Author:
Penel Nicolas,Vanseymortier Marie,Bonneterre Marie-Edith,Clisant Stéphanie,Dansin Eric,Vendel Yvette,Beuscart Régis,Bonneterre Jacques
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference22 articles.
1. Weinfurt KP, Depuy V, Castel LD, Sulmasy DP, Schulman KA, Meropol NJ (2005) Understanding of an aggregate probability statement by patients who are offered participation in phase I clinical trials. Cancer 103:140–147
2. Kurzrock R, Benjamin RS (2005) Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 352:930–932
3. Dillman RO, Koziol JA (1992) Phase I cancer trials: limitations and implications. Mol Biother 4:117–121
4. Lipsett MB (1995) On the nature and ethics of phase I trials. J Clin Oncol 13:1049–1051
5. Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R (1996) Therapeutic responses in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105–1115
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献